Covalon to Host Symposium on Chronic Wound Management at EWMA 2016 in Bremen, Germany
2016年5月11日 - 10:07PM
ビジネスワイヤ(英語)
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV), an advanced medical technologies company, today announced its
participation at the European Wound Management Association (“EWMA”)
annual conference, including the sponsorship of a satellite
symposium entitled “Management of Proteases in the Chronic Wound”
presented by Dr. Terry Treadwell, MD, FACS, Medical Director,
Institute for Advanced Wound Care.
“We hope all delegates with an interest in healing recalcitrant
wounds will attend Dr. Treadwell’s talk,” said John R. Hands,
Executive Vice President of Covalon. Dr. Treadwell’s presentation
will take place on Thursday May 12 at 3:45pm in the Franzius
room.
“We also invite everyone to stop by Covalon’s booth 5K13 to
learn about our advanced wound care portfolio, which includes our
CovaWound line of products and ColActive Plus, our patented
biomatrix dressing proven to reduce elevated protease activity in a
chronic wound, a known cause of wound chronicity,” Hands
continued.
In addition to the symposium, there will be three scientific
posters presented on Covalon’s products at this year’s EWMA:
- An in vitro analysis of the antimicrobial activity of a silver
containing collagen dressing over seven days - Dr. Casandra
Gardner.
- Assessment of a novel biomatrix wound contact layer using
simulated NPWT – Dr. Casandra Gardner.
- The antimicrobial protective properties of a novel
pre-operative skin preparation product with chlorhexidine and
silver – Dr. Casandra Gardner.
“The timing of EWMA presents a great opportunity for us to build
on our successful presence at the SAWC Spring congress last month
in Atlanta. This is our second year exhibiting at EWMA and we see
an immediate need in the European market for our CovaWound line of
advanced wound care products,” said Hands.
Covalon will also be showcasing its dual antimicrobial clear
silicone adhesive technologies including SurgiClear™ Antimicrobial
Post Op Dressing. SurgiClear’s combination of chlorhexidine and
silver is proven to have a synergistic effect against some of the
most common surgical site infection bacteria1 and SurgiClear’s soft
silicone adhesive will not cause adhesive related skin injury or
pain during dressing changes2.
Visit Covalon at booth 5K13 at the EWMA Conference May 11-13 at
Messe Bremen, Germany.
About CovalonCovalon Technologies Ltd. researches,
develops and commercializes new healthcare technologies that help
save lives around the world. Covalon's patented technologies,
products and services address the advanced healthcare needs of
medical device companies, healthcare providers and individual
consumers. Covalon's technologies are used to prevent, detect and
manage medical conditions in specialty areas such as wound care,
tissue repair, infection control, disease management, medical
device coatings and biocompatibility. To learn more about Covalon,
visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
1 A Laboratory Study of the Synergistic Effect of Chlorhexidine
and Silver, Blom, Kristina Werthen, Maria et al.American Journal of
Infection Control, Volume 43 , Issue 6 , S22
2 A Human Repeat Patch Test Study, DiTizio et al.
http://www.wounds-uk.com/case-series/harrogate-2014-conference-posters
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160511005871/en/
Covalon Technologies Ltd.Brian Pedlar, 905-568-8400 x
233CEObpedlar@covalon.comToll free: 1.877.711.6055Web site:
www.covalon.comTwitter: @covalon
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 1 2025 まで 2 2025
Covalon Technologies (TSXV:COV)
過去 株価チャート
から 2 2024 まで 2 2025